Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Haplotype-resolved long-read sequencing reveals parent-of-origin effects of tandem-repeat variation in autism spectrum disorder.

Science bulletin·2026
Same author

The genetic spectrum of LRRK2 variants in Parkinson's disease: findings from a large Chinese cohort.

NPJ Parkinson's disease·2026
Same author

Large-scale profiling of blood microbial signatures in patients with Parkinson's disease and its association with disease progression: a cross-sectional study.

EBioMedicine·2026
Same author

Shared genetic architecture between sleep traits and cardiometabolic diseases.

EBioMedicine·2026
Same author

Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson's disease: a randomized phase 2 trial.

Signal transduction and targeted therapy·2026
Same author

Short tandem repeat expansions in patients with neurodegenerative dementia.

EBioMedicine·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Bin Jiao1, Ziyu Ouyang1, Shilin Luo1

  • 1Xiangya Hospital, Central South University, Changsha, Hunan, China.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

来自血光谱的机器学习数字生物标志物为早期阿尔茨海默病 (AD) 检测和与其他神经退行性疾病区分提供了低成本的方法. 这种方法提高了诊断在临床环境中的可访问性和准确性.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

科学领域:

  • 生物标志物和诊断方法
  • 机器学习在医学中的应用
  • 神经退行性疾病 神经退行性疾病

背景情况:

  • 阿尔茨海默病 (AD) 诊断依赖于复杂的生物途径改变,需要有效的血液生物标志物.
  • 目前的血液生物标志物方法在成本效益和操作复杂性方面存在局限性,这阻碍了广泛的临床采用.

研究的目的:

  • 开发低成本,方便的基于机器学习的数字生物标志物 (MLDB),使用等离子体光谱.
  • 在健康的对照人群中检测AD或轻度认知障碍 (MCI).
  • 将AD与其他神经退行性疾病区分开来,例如莱维体痴呆症 (DLB),前性痴呆症 (FTD) 和渐进性上核性麻 (PSP).

主要方法:

  • 利用了来自1,324个人的减弱总反射度-里埃变换红外线 (ATR-FTIR) 血光谱数据.
  • 使用随机森林分类器和特征选择来识别数字生物标志物.
  • 在研究队列中包括患有AD,MCI,DLB,FTD,PSP和HC的参与者.

主要成果:

  • MLDB实现了高诊断准确度:AD与HC的AUC为0.92,MCI与HC的AUC为0.89.
  • 证明了区分AD和其他神经退行性疾病的能力,AUC从0.80到0.93.9不等.
  • 确定了与血p-tau217和GFAP水平负相关的数字生物标志物.

结论:

  • 通过ATR-FTIR等离子体光谱特征,可以识别AD相关的病理变化.
  • 这些光谱特征作为AD的有效数字生物标志物起作用.
  • 开发的MLDB方法显著有助于早期查和诊断AD,改善可访问性.